title: The effects of corticosteroid on tissue lactoferrin in patients with nasal polyposis.
abstract: BACKGROUND
  Although, lactoferrin (LF) is the second most important antimicrobial and anti-inflammatory peptide after lysozyme in upper respiratory tract, little is known about its role in chronic rhinosinusitis (CRS). Recent studies pronounced that LF levels were significantly  reduced in CRS with nasal polyposis (NP) compared with other subgroups. However, effects of systemic corticosteroid (CS) treatment, which is currently the main NP treatment modality, and subsequent surgical intervention on LF levels are still not known. This study was designed to evaluate  the effects of CS treatment and surgical intervention on LF levels in patients with NP.
  
  
  METHODS
  Patients with inflammatory NP who were scheduled to undergo CS treatment and a control group were included in this study. LF levels were determined from mucosal samples taken  from both groups, before and after CS treatment, and also 1 month after surgical intervention.
  
  
  RESULTS
  Twenty-seven patients with NP and 14 patients who underwent septoplasty were included in the study. Tissue LF levels were significantly lower in the NP group compared  with the control group (p = 0.014). Tissue LF levels did not change significantly in NP patients after CS treatment. However, a significant reduction in tissue LF was detected 1 month after endoscopic sinus surgery.
  
  
  CONCLUSIONS
  Tissue LF concentrations significantly decreased  in patients with NP. CS treatment had no effect on tissue LF levels, whereas postendoscopic sinus surgery, tissue LF levels were getting lower because there was also a reduction in inflammatory load (whether from reduction in mucosa surface area or resolution of disease).
authors.affiliation: Department of Otorhinolaryngology, Istanbul Training and Research Hospital, Istanbul, Turkey. drengin@hotmail.com
authors.forename: Engin
authors.initials: E
authors.lastname: Acıoğlu
authors.forename: Ozgür
authors.initials: O
authors.lastname: Yigit
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Alkan
authors.forename: Elad
authors.initials: E
authors.lastname: Azizli
authors.forename: Ramisa
authors.initials: R
authors.lastname: Gelişgen
authors.forename: Hafize
authors.initials: H
authors.lastname: Uzun
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D002908:Chronic Disease; D015536:Down-Regulation; D004724:Endoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007781:Lactoferrin / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D009300:Nasal Septum / Q000033:anatomy & histology / Q000601:surgery*; D019651:Plastic Surgery Procedures; D012220:Rhinitis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D012852:Sinusitis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007781:Lactoferrin